Study summary

The objectives of this study are to determine the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in participants with solid tumors.

Additional Study Details

Phase
1
Product
  • ASP5878
  • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    86
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): Japanese

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for An Open-label Phase I Study of orally available novel small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 inhibitor, ASP5878 at Single and Multiple Doses in Patients with Solid Tumors? Contact us by filling out your information to the right and we’ll respond to you.

    • A caregiver
    • A healthcare provider
    • A parent
    • A patient
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site JP117
      Niigata, Niigata, Japan
      Completed
      Site JP118
      Osaka, Osaka, Japan
      Completed
      Site JP112
      Nagoya, Nagoya, Japan
      Completed
      Site KR202
      Gyeonggi-do, Gyeonggi-do, Republic of Korea
      Completed
      Site JP106
      Osaka, Osaka, Japan
      Completed
      Site JP107
      Tokyo, Tokyo, Japan
      Withdrawn
      Site US405
      Cleveland, OH, United States, 44195
      Completed
      Site JP121
      Okayama, Okayama, Japan
      Completed
      Site JP124
      Shizuoka, Shizuoka, Japan
      Completed
      Site JP113
      Hyogo, Hyogo, Japan
      Completed
      Site KR204
      Seoul, Seoul, Republic of Korea
      Completed
      Site TW302
      Tainan, Tainan, Taiwan, Province of China
      Completed
      Site US402
      Orange, CA, United States, 92868
      Completed
      Site JP123
      Tokyo, Tokyo, Japan
      Completed
      Site TW301
      Taipei, Taipei, Taiwan, Province of China
      Completed
      Site JP103
      Ibaraki, Ibaraki, Japan
      Completed
      Site JP120
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP111
      Ishikawa, Ishikawa, Japan
      Completed
      Site US406
      Spartanburg, SC, United States, 29303
      Completed
      Site JP104
      Osaka, Osaka, Japan
      Completed
      Site US410
      Fairfax, VA, United States, 22031
      Completed
      Site TW303
      Taipei, Taipei, Taiwan, Province of China
      Completed
      Site KR201
      Seoul, Seoul, Republic of Korea
      Completed
      Site KR203
      Seoul, Seoul, Republic of Korea
      Completed
      Site JP119
      Kanagawa, Kanagawa, Japan
      Completed
      Site US401
      New York, NY, United States, 10032
      Withdrawn
      Site US412
      Detroit, MI, United States, 48201
      Completed
      Site JP109
      Miyagi, Miyagi, Japan
      Completed
      Site JP102
      Tokyo, Tokyo, Japan
      Completed
      Site JP101
      Kyoto, Kyoto, Japan
      Completed
      Site US404
      Cleveland, OH, United States, 44106
      Completed
      Site JP122
      Chiba, Chiba, Japan
      Completed
      Site JP110
      Miyagi, Miyagi, Japan
      Completed
      Site JP108
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP116
      Hokkaido, Hokkaido, Japan
      Withdrawn
      Site JP114
      Tokyo, Tokyo, Japan
      Completed
      Site US403
      Seattle, WA, United States, 98109
      Completed
      Site JP115
      Fukuoka, Fukuoka, Japan

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?